SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-187704
Filing Date
2023-07-17
Accepted
2023-07-17 08:07:00
Documents
14
Period of Report
2023-07-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d508610d8k.htm   iXBRL 8-K 33588
2 EX-10.1 d508610dex101.htm EX-10.1 461336
6 GRAPHIC g508610im02.jpg GRAPHIC 698
  Complete submission text file 0001193125-23-187704.txt   731189

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA tvtx-20230716.xsd EX-101.SCH 2851
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE tvtx-20230716_lab.xml EX-101.LAB 17995
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tvtx-20230716_pre.xml EX-101.PRE 11262
8 EXTRACTED XBRL INSTANCE DOCUMENT d508610d8k_htm.xml XML 3362
Mailing Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130
Business Address 3611 VALLEY CENTRE DR SUITE 300 SAN DIEGO CA 92130 888-969-7879
Travere Therapeutics, Inc. (Filer) CIK: 0001438533 (see all company filings)

IRS No.: 262383102 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36257 | Film No.: 231090570
SIC: 2834 Pharmaceutical Preparations